What's Happening?
Discovery Life Sciences has launched the Luminos® Comprehensive, a 164-gene pan-tumor comprehensive genomic profiling panel. This panel is validated on FFPE tissue as an IVDR-compliant laboratory-developed test and is deployed in-house at the company's
Kassel, Germany facility. The panel is designed to deliver results within 7 to 10 business days, addressing a significant gap in the EU oncology trials landscape where IVDR compliance is required. The Luminos® Comprehensive panel supports enrollment screening, biomarker stratification, and prospective EU clinical use without the need for third-party reference lab routing. This development is particularly significant as it offers a faster turnaround compared to the typical 20-to-30-day period offered by most European reference labs.
Why It's Important?
The introduction of the Luminos® Comprehensive panel is crucial for pharmaceutical sponsors and CROs conducting oncology trials in Europe. The EU In Vitro Diagnostic Regulation (IVDR) compliance is mandatory for genomic testing in clinical trials, but many labs struggle to meet these requirements in-house, leading to delays in trial enrollment and increased costs. By providing a rapid, in-house solution, Discovery Life Sciences helps streamline the trial process, potentially accelerating the development of new cancer therapies. This advancement not only benefits European trials but also impacts U.S.-based biotechs with trial sites in Europe, as they face the same regulatory requirements.
What's Next?
Discovery Life Sciences plans to expand its Luminos® platform with the upcoming launch of Luminos® Liquid, a cfDNA/cfRNA liquid biopsy panel, expected in Fall 2026. This will further enhance their offering by providing IVDR-compliant solutions for a broader range of specimen types. The company will also engage with pharma sponsors and CROs at the ASCO Annual Meeting in Chicago to discuss the technical specifications and benefits of their new genomic solutions.
